ʻO Cagrilintide 10mg

▎ Kūlana Cagrilintide

▎ Noiʻi Cagrilintide

He aha ke kumu noiʻi o Cagrilintide?

ʻO Cagrilintide kahi ʻelua amylin a me ka calcitonin receptor agonist (DACRA) i kūkulu ʻia ma muli o ke ʻano o ka amylin. Ua huna ʻia ʻo Amylin e nā ʻāpana pancreatic islet β a hana pū me ka insulin e hana i nā hana physiological like ʻole. Hiki iā ia ke hoʻoulu i ka manaʻo o ka māʻona a hoʻemi i ka ʻai ʻana i ka meaʻai, ʻoi loa ma ka hoʻoulu ʻana i nā mea loaʻa i ka postrema wahi ma ke kumu o ka ventricle ʻehā. Hoʻouna ʻia nā hōʻailona neural i ka forebrain ma o ka nucleus o ka ʻāpana mehameha a hiki ke hoʻouna ʻia i ka ʻāpana hypothalamic lateral a me nā pūʻulu nuklea ʻē aʻe ma o ka nucleus parabrachial lateral, no laila e hoʻohauʻoli ai i ke kikowaena satiety a me ke kāohi ʻana i ka ʻai ʻai ^[1] . Hiki nō hoʻi iā Amylin ke hoʻoponopono i ka homeostasis glucose ma ke kāohi ʻana i ka huna ʻana o ka insulin a me ka glucagon e mālama i nā pae glucose koko paʻa ^[2] . Loaʻa i kāna mau hana ka hopena pololei i nā ʻāpana pancreatic islet α a me kahi hoʻoponopono pololei ʻole o ka huna ʻana o ka glucagon ma o nā hōʻailona neural i ka hypothalamus. I nā poʻe maʻi me ka maʻi diabetes, ʻo ka luku ʻana i nā cell β e alakaʻi i ka emi ʻana o ka huna ʻana o ka amylin. Hoʻokomo ʻo Amylin i ka hoʻoponopono ʻana i ka homeostasis glucose ma ke kāohi ʻana i ka hoʻokuʻu ʻana o ka ʻōpū a me ka hana ʻana o ka glucose hepatic postprandial, e hōʻemi ana i ka fluctuations koko postprandial. Hiki iā ia ke hoʻopaneʻe i ka hoʻokuʻu ʻana o ka ʻōpū, ke kāohi i ka peristalsis o ka ʻōpū, hoʻolōʻihi i ka manawa noho o ka meaʻai, a pale i ka piʻi nui o ke koko glucose. Eia nō naʻe, ʻo ka hapalua o ke ola o ka amylin maoli e kaupalena i kāna noi lapaʻau. ʻOiai ua loaʻa ka pramlintide ma ke ʻano he lāʻau adjuvant, pono ia i ʻekolu injections i ka lā, he mea kūpono ʻole a hopena i ka hoʻokō maikaʻi ʻole ^[3] . No ka hoʻoponopono ʻana i kēia pilikia, ua kūkulu ʻia ʻo Cagrilintide. Hoʻokumu ʻia kāna noiʻi a me ka hoʻomohala ʻana i ka ʻike hohonu o nā hana physiological o ka amylin maoli, e manaʻo ana e hoʻohālikelike i kāna ʻano hana i ka wā e hoʻomaikaʻi ai i ka paʻa a me nā waiwai lōʻihi o ka lāʻau e hoʻokō ai i nā pono lapaʻau.

He aha ka Cagrilintide?

ʻO Cagrilintide kahi mea hoʻohālikelike amylin hana lōʻihi me ka mana nui, ua hōʻike mua i ka hopena mua i ka mālama ʻana i ka momona a me ka maʻi diabetes. Ua lipidated a loaʻa iā ia nā ʻano paʻa a lōʻihi ^[3] . Hoʻokuʻu pū ʻia ʻo Amylin me ka insulin e nā pancreatic β cell a hoʻoulu i ka manaʻo o ka māʻona ma o ka hana ʻana i ka homeostatic a me nā wahi leʻaleʻa o ka lolo. Ma ke ʻano he analog, hiki iā Cagrilintide ke hoʻohālike i kēia hopena, e hoʻoulu ai i ka satiety e kōkua i ke kāohi ʻana i ke kaumaha o ke kino. I ka manawa like, ma ke ʻano he ʻelua amylin a me ka calcitonin receptor agonist (DACRA), loaʻa ia mai ka iwi kuamoʻo amylin a loaʻa iā ia kahi hana kūʻokoʻa i ka hoʻoponopono metabolic.

Ke Ana Hoʻohālike o Cagrinlintide

Puna:PubMed ^[3]

He aha nā mea pili o Cagrilintide?

I nā hoʻokolohua lapaʻau, ua loaʻa ʻo Cagrilintide i nā hopena maikaʻi i ka hoʻoulu ʻana i ke kaumaha. No ka laʻana, i loko o kahi multicenter, randomized, double-blind, placebo-controlled, and active comparator Phase 2 dose-fining trial, i hoʻohālikelike ʻia me ka hui placebo, ʻoi aku ka kiʻekiʻe o ka pākēneka o ka pohō kaumaha mai ka baseline i kēlā me kēia hui o Cagrilintide (0.3 - 4.5 mg) (6.0% - 10.8%) i ʻoi aku ka kiʻekiʻe ma mua o ka hui placebo. ʻOi aku ka nui o ka pohō kaumaha ma ka hui 4.5 mg ma mua o ka liraglutide 3.0 mg (10.8% vs. 9.0%), e hōʻike ana he hiki ke koho maikaʻi no ka mālama ʻana i ke kaumaha ^[4] . He ʻokoʻa ka hana o ka Cagrilintide akā pili i ka GLP-1 receptor agonist semaglutide. Hoʻemi ʻo Semaglutid i ka ʻai, hoʻonui i ka huna ʻana o ka insulin, a hoʻopaneʻe i ka hoʻokuʻu ʻana o ka ʻōpū ma ka hana ʻana i nā mea hoʻokipa GLP-1 i ka hypothalamus, ʻoiai ʻo Cagrilintide e hōʻemi hou i ka makemake ma o ka hoʻāla ʻana i ka mea loaʻa amylin. Hiki i ka hoʻohana hui ʻana o nā mea ʻelua ke hana i kahi hopena superimposed, e hoʻonui nui i ka hopena kaumaha ^[5] . Hāʻawi ʻia i ka paʻakikī o ka momona, ʻo kēia lāʻau hoʻohui ʻia he hoʻolālā kūpono a maikaʻi.

I nā poʻe maʻi me ka maʻi diabetes type 2, ua hōʻike pū ʻo Cagrilintide i ka hiki ke hoʻomalu i ka glucose koko. Ua hōʻike ʻia nā haʻawina lāʻau lapaʻau he kūpaʻa maikaʻi a maikaʻi hoʻi i ka mālama ʻana i ka momona a me ka maʻi diabetes type 2. No ka laʻana, i loko o kahi hoʻokolohua hoʻokolohua o nā maʻi me ka maʻi diabetes type 2, ʻo ka hoʻohana ʻana o Cagrilintide a me ka GLP-1 receptor agonist semaglutide i hōʻike i ka mana glucose koko maikaʻi a me nā hopena kaumaha ^[6] . Ua hōʻike pū kekahi hoʻokolohua ʻē aʻe i kona hoʻomanawanui maikaʻi a me ka palekana ke hoʻohana wale ʻia a i hui pū ʻia me ka semaglutide ^[6] , no ka mea, pili pono ke kūpaʻa o ka lāʻau lapaʻau i kona ʻae a me ka palekana.

Eia kekahi, ua ʻae maikaʻi ʻia ʻo Cagrilintide i nā hoʻokolohua lapaʻau. I ka Phase 2 dose-fining trial, ua like ka nui o ka hoʻopau ʻana i kēlā me kēia hui lapaʻau, ʻo ka hapa nui ma muli o nā hanana ʻino. Eia nō naʻe, ʻo nā maʻi ʻino i maʻamau ka maʻi ʻōpū a me nā hopena o ka wahi injection, a ʻo ka hapa nui o lākou he maʻi a maʻalahi. I loko o kahi ho'āʻo hoʻokolohua Phase 1b i hoʻopaʻa ʻia, ʻo ka hui pū ʻana o Cagrilintide a me 2.4 mg semaglutide i hōʻike pū i ka hoʻomanawanui a me ka palekana ^[7] . Pono nā hoʻokolohua ʻoi aku ka nui a me ka lōʻihi i ka wā e hiki mai ana no ka loiloi piha ʻana i ka pono a me ka palekana o kēia lapaʻau hui.

Lawe mai ʻo Cagrilintide i ka manaʻolana hou no ka mālama ʻana i ka momona a me ka maʻi diabetes type 2. Hāʻawi ia i kahi koho lapaʻau hou no nā maʻi obese, ʻoi aku ka poʻe i pane maikaʻi ʻole i ka hana ʻana i ke ʻano o ka nohona a ʻaʻole kūpono no ka ʻoki bariatric. Hāʻawi kona ʻano hana kūʻokoʻa i nā manaʻo a me nā ʻano hana no ka mālama ʻana i ka momona, a ʻoi aku paha ka maikaʻi ma mua o nā lāʻau hoʻēmi kaumaha maʻamau (D'Ascanio AM, 2024). ʻO ka hihia kūleʻa o ka hoʻohana pū ʻana o Cagrilintide a me semaglutide (CagriSema) e hōʻike ana i ka hoʻomaʻamaʻa hui pū ʻia he mea hoʻolālā maikaʻi e hoʻomaikaʻi ai i ka pane ʻana no ka momona ^[6] . Hāʻawi kēia kumu hoʻohālike i kahi paradigm hou no ka mālama ʻana i ka momona a lawe pū kekahi i nā hoʻomaikaʻi metabolic koʻikoʻi i nā poʻe maʻi me ka maʻi diabetes type 2.

I ka hopena, ma ke ʻano he mea hoʻohālikelike amylin hana lōʻihi, ʻo Cagrilintide ka mana koʻikoʻi no ka pohō kaumaha a me ka hoʻokele glucose koko. Hoʻola ia i ke ala hōʻailona maʻaʻa ma ka hoʻohālikelike ʻana i ka hana a amylin a hoʻoponopono i ka metabolism ma ke ʻano he agonist ʻelua. Ua hōʻike ʻia nā hoʻokolohua lapaʻau ʻo Cagrilintide, ʻo ia wale nō a i hui pū ʻia me ka semaglutide, hiki ke hōʻemi nui i ke kaumaha o ke kino a ua ʻae maikaʻi ʻia. Eia kekahi, ua hōʻike pū ʻia ka hiki ke hoʻomalu i ka glucose koko i nā poʻe maʻi me ka maʻi diabetes type 2, e hāʻawi ana i kahi koho lapaʻau hou no ka mālama ʻana i ka momona a me ka maʻi diabetes, e hoʻopiha ana i ke āpau i nā regimens lapaʻau e kū nei, ʻoi aku hoʻi no nā poʻe maʻi i pane maikaʻi ʻole i ke ʻano o ke ola ʻana a ʻaʻole kūpono no ka ʻoki. Hāʻawi kāna papahana lapaʻau multi-target i nā manaʻo hou no ka mālama ʻana i nā maʻi metabolic.

No ka mea kakau

ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.

Mea kākau moʻolelo ʻepekema

He kaukaʻi ʻo Kauka DCW Lau ma ke kula ʻo Cumming School of Medicine, University of Calgary, Canada. ʻO kāna mau noiʻi noiʻi e pili ana i ka endocrinology a me ka metabolism, ka lāʻau lapaʻau maʻamau a me loko, ka ʻōnaehana cardiovascular a me ka cardiology, ke olakino lehulehu, ke olakino a me ka ʻoihana, a me ka oncology. Loaʻa iā ia nā kūlana me Alberta Health Services (AHS) a me Obesity Canada a hana ʻo ia ma ka Julia McFarlane Diabetes Research Center. He ʻike nui ʻo Dr. Lau ma nā ʻano o ka maʻi maʻi a me ka noiʻi ʻana i ka momona, me kāna hana i paʻi ʻia ma nā puke moʻolelo hoʻonaʻauao e like me ka Canadian Journal of Diabetes. Ua helu ʻia ʻo Kauka DCW ma ka ʻōlelo kuhikuhi [4].

▎ Nā ʻōlelo pili

[1] Hansen KE, Murali S, Chaves IZ, et al. Glycomacropeptide Impacts Amylin-Mediated Satiety, Postprandial Markers of Glucose Homeostasis, and the Fecal Microbiome in Obese Postmenopausal Women[J]. Ka Nupepa Nutrition, 2023,153(7):1915-1929.DOI:10.1016/j.tjnut.2023.03.014.

[2] Ling W, Huang Y, Qiao Y, et al. Amylin Kanaka: Mai ka Pathology a hiki i ka Physiology and Pharmacology[J]. ʻEpekema Protein & Peptide o kēia manawa, 2019,20(9):944-957.DOI:10.2174/ 13892037206 66 19032811183 3.

[3] Kruse T, Hansen JL, Dahl K, et al. Ka hoʻomohala ʻana o Cagrilintide, kahi Amylin Analogue lōʻihi [J]. Nūpepa o ka lāʻau Kemika, 2021,64(15):11183-11194.DOI:10.1021/acs.jmedchem.1c00565.

[4] Lau DCW, Erichsen L, Francisco AM, et al. ʻO ka cagrilintide hoʻokahi pule no ka hoʻokele paona i nā poʻe me ke kaumaha a me ka momona: kahi multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-fining phase 2 ho'āʻo [J]. Lancet, 2021,398(10317):2160-2172.DOI:10.1016/S0140-6736(21)01751-7.

[5] D'Ascanio AM, Mullally JA, Frishman W H. Cagrilintide: He Amylin Analog lōʻihi no ka mālama ʻana i ka momona [J]. ʻO ka Cardiology in Review, 2024,32(1):83-90.DOI:10.1097/CRD.0000000000000513.

[6] Frias JP, Deenadayalan S, Erichsen L, et al. ʻO ka maikaʻi a me ka palekana o ka cagrilintide 2.4 mg i hoʻokahi pule i hoʻokahi pule me ka semaglutide 2.4 mg i hoʻokahi pule i ka maʻi diabetes type 2: kahi multicentre, randomised, double-blind, active-controlled, phase 2 trial [J]. Lancet, 2023,402(10403):720-730.DOI:10.1016/S0140-6736(23)01163-7.

[7] Enebo LB, Berthelsen KK, Kankam M, et al. Ka palekana, ka hoʻomanawanui, ka pharmacokinetics, a me ka pharmacodynamics o ka hoʻokele like ʻana o ka nui o ka cagrilintide me ka semaglutide 2.4 mg no ka hoʻokele paona: kahi randomised, controlled, phase 1b trial [J]. Lancet, 2021,397(10286):1736-1748.DOI:10.1016/S0140-6736(21)00845-X.

ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.  

ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a maʻi paha. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.